Dravet syndrome is a developmental and epileptic encephalopathy (DEE) characterized by intractable seizures, comorbidities related to developmental, cognitive, and motor delays, and a high mortality burden due to sudden unexpected death in epilepsy (SUDEP). Most Dravet syndrome cases are attributed toSCN1Ahaploinsufficiency, with genetic modifiers and environmental factors influencing disease severity. Mouse models with heterozygous deletion ofScn1arecapitulate key features of Dravet syndrome, including seizures and premature mortality; however, severity varies depending on genetic background. Here, we refined two Dravet survival modifier (Dsm) loci,Dsm2on chromosome 7 andDsm3on chromosome 8, using interval-specific congenic (ISC) mapping.Dsm2was complex and encompassed at least two separate loci, whileDsm3was refined to a single locus. Candidate modifier genes within these refined loci were prioritized based on brain expression, strain-dependent differences, and biological relevance to seizures or epilepsy. High priority candidate genes forDsm2includeNav2, Ptpn5, Ldha, Dbx1, Prmt3 and Slc6a5, whileDsm3has a single high priority candidate,Psd3. This study underscores the complex genetic architecture underlying Dravet syndrome and provides insights into potential modifier genes that could influence disease severity and serve as novel therapeutic targets.